AbbVie's eight-week HCV regimen leads to 98% SVR12

AbbVie Inc. (NYSE:ABBV) and partner Enanta Pharmaceuticals Inc. (NASDAQ:ENTA) said an eight-week regimen of Viekirax ombitasvir/paritaprevir/ritonavir plus Exviera dasabuvir led to an SVR12 in 160 (98%) of 163 evaluable HCV patients in the Phase IIIb GARNET study to treat HCV genotype 1b infection, meeting the primary endpoint.

The partners said two patients experienced post-treatment relapse. One patient discontinued the study due to noncompliance. ...